Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Biogen ( (BIIB) ) has shared an announcement.
On June 17, 2025, Biogen Inc. held its 2025 Annual Meeting of Stockholders, where eleven nominees were elected to the Board of Directors for a one-year term. Additionally, stockholders ratified the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, and approved the advisory vote on executive compensation. These decisions reflect the company’s ongoing governance and financial oversight strategies.
The most recent analyst rating on (BIIB) stock is a Buy with a $294.00 price target. To see the full list of analyst forecasts on Biogen stock, see the BIIB Stock Forecast page.
Spark’s Take on BIIB Stock
According to Spark, TipRanks’ AI Analyst, BIIB is a Neutral.
Biogen’s stability and strategic product advancements are strengths, but the declining revenue trend and competitive pressures in its core segments present significant challenges. The company’s valuation and earnings call sentiment offer some optimism, but a cautious approach is warranted given the current market dynamics.
To see Spark’s full report on BIIB stock, click here.
More about Biogen
Biogen Inc. is a biotechnology company primarily focused on discovering, developing, and delivering innovative therapies for neurological and neurodegenerative diseases. The company operates in the healthcare industry, with a market focus on treatments for conditions such as multiple sclerosis, Alzheimer’s disease, and other serious neurological disorders.
Average Trading Volume: 1,684,451
Technical Sentiment Signal: Sell
Current Market Cap: $18.61B
Find detailed analytics on BIIB stock on TipRanks’ Stock Analysis page.